Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00402363
First received: November 20, 2006
Last updated: February 7, 2013
Last verified: February 2012
  Purpose

The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.


Condition Intervention Phase
Fibrillation, Atrial
Atrial Fibrillation
Drug: omega-3-acid ethyl esters
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Efficacy and Safety of Lovaza for the Prevention of Recurrent, Symptomatic Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF /Flutter was defined as AF/Flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.


Secondary Outcome Measures:
  • Number of Participants With Persistent AF and in Both AF Subgroups Combined With an Event of Documented Symptomatic AF/Flutter [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF/flutter (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. The occurrence of symptomatic atrial flutter was treated as an occurrence of symptomatic AF for this outcome measure. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF or flutter.

  • Number of Participants With Paroxysmal AF or Persistent AF With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter) [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.

  • Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic AF (Exclusive of Atrial Flutter) [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic recurrence of AF (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.

  • Number Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF/Flutter [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.

  • Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF/Flutter [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF/flutter (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic or asymptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF or flutter were recorded by TTM during routine bi-weekly transmissions. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.

  • Number of Participants With Paroxysmal or Persistent AF With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter) [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.

  • Number of Participants in Both AF Subgroups Combined With an Event of Documented Symptomatic or Asymptomatic AF (Exclusive of Flutter) [ Time Frame: From first dose of study drug (Day 1) to the first symptomatic or asymptomatic recurrence of AF (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic or asymptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Asymptomatic episodes of AF were recorded by TTM during routine bi-weekly transmissions. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic or asymptomatic AF/flutter.

  • Number of Participants With Paroxysmal or Persistent AF With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter [ Time Frame: From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.

  • Number of Participants in the Combined AF Subgroups With an Event After Completion of Day 7 to the Occurrence of Symptomatic AF/Flutter [ Time Frame: From completion of Day 7 of study drug to the first symptomatic recurrence of AF/flutter (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF/flutter was defined as AF/flutter documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. Atrial flutter, a closely related rhythm disorder, was distinguished from AF by the presence of distinctive flutter p-waves at regluar intervals. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF/flutter.

  • Number of Participants With Paroxysmal or Persistent AF With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter) [ Time Frame: From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.

  • Number of Participants in the Combined AF Subgroups With an Event That Occurred After Completion of Day 7 to the Occurrence of Symptomatic AF (Exclusive of Flutter) [ Time Frame: From completion of Day 7 of study drug to the first symptomatic recurrence of AF (up to Week 24) ] [ Designated as safety issue: No ]
    A documented episode of symptomatic AF was defined as AF documented by an electrocardiogram (ECG) or transtelephonic monitoring (TTM) tracing associated with symptoms consistent with AF. "Censored" in the table below refers to participants who did not have a documented episode of symptomatic AF.

  • Annualized Number of AF/Flutter Rescue Episodes During the Treatment Period [ Time Frame: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24) ] [ Designated as safety issue: No ]
    Rescue was defined as any pharmacological/electrical/surgical intervention for the termination/prevention of AF/flutter with a maximum of one rescue episode counted per day. Note: all annualized values were calculated by counting the number of rescue episodes, dividing by the number of days on treatment, then multiplying that number by 365.25.

  • Annualized Cumulative Frequency of Symptomatic AF/Flutter Recurrences During the Treatment Period [ Time Frame: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24) ] [ Designated as safety issue: No ]
    Values were annualized by counting the number of episodes of symptomatic AF/flutter recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.

  • Annualized Cumulative Frequency of Symptomatic AF Recurrences During the Treatment Period [ Time Frame: From first dose of study drug (Day 1) to the last dose of study drug (up to Week 24) ] [ Designated as safety issue: No ]
    Values were annualized by counting the number of episodes of symptomatic AF recurrences (maximum of one per day), dividing by the number of days on treatment, then multiplying this number by 365.25.


Enrollment: 663
Study Start Date: November 2006
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omega-3-acid ethyl esters Drug: omega-3-acid ethyl esters
Placebo Comparator: Placebo Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women age 18 years or older
  • History of symptomatic atrial fibrillation (either paroxysmal or persistent)
  • Provide written informed consent and authorization for protected health information disclosure

Exclusion Criteria:

  • Permanent (chronic) atrial fibrillation
  • Antiarrhythmic drug therapy which cannot be stopped
  • Use of amiodarone with prior 6 months
  • History of unsuccessful cardioversion
  • History of certain cardiovascular conditions or cardiac surgery within prior 6 months
  • History of stroke within prior 6 months
  • Implanted cardio-defibrillator
  • Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic conditions, or cancer (except non-melanoma skin cancer)
  • Poorly controlled diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00402363

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Birmingham, Alabama, United States, 35215
GSK Investigational Site
Huntsville, Alabama, United States, 35801
United States, Alaska
GSK Investigational Site
Anchorage, Alaska, United States, 99508
United States, Arizona
GSK Investigational Site
Cottonwood, Arizona, United States, 86326
GSK Investigational Site
Mesa, Arizona, United States, 85206
GSK Investigational Site
Phoenix, Arizona, United States, 85006
GSK Investigational Site
Phoenix, Arizona, United States, 85014
GSK Investigational Site
Phoenix, Arizona, United States, 85032
GSK Investigational Site
Tucson, Arizona, United States, 85724
United States, Arkansas
GSK Investigational Site
Fort Smith, Arkansas, United States, 72901
GSK Investigational Site
Hot Springs, Arkansas, United States, 71913
United States, California
GSK Investigational Site
Alamada, California, United States, 94501
GSK Investigational Site
Bakersfield, California, United States, 93301
GSK Investigational Site
Bakersfield, California, United States, 93308
GSK Investigational Site
Beverly Hills, California, United States, 90210
GSK Investigational Site
Carmichael, California, United States, 95608
GSK Investigational Site
Fair Oaks, California, United States, 95628
GSK Investigational Site
Fountain Valley, California, United States, 92708
GSK Investigational Site
Loma Linda, California, United States, 92354
GSK Investigational Site
Los Angeles, California, United States, 90033
GSK Investigational Site
Los Angeles, California, United States, 90211
GSK Investigational Site
Los Angeles, California, United States, 90048
GSK Investigational Site
Los Angeles, California, United States, 90073
GSK Investigational Site
Merced, California, United States, 95348
GSK Investigational Site
Palm Springs, California, United States, 92262
GSK Investigational Site
Poway, California, United States, 92064
GSK Investigational Site
Redondo Beach, California, United States, 90277
GSK Investigational Site
Sacramento, California, United States, 95819
GSK Investigational Site
San Diego, California, United States, 92123
GSK Investigational Site
San Diego, California, United States, 92120
GSK Investigational Site
San Diego, California, United States, 92161
GSK Investigational Site
Vista, California, United States, 92081
GSK Investigational Site
Walnut Creek, California, United States, 94598
United States, Colorado
GSK Investigational Site
Aurora, Colorado, United States, 80012
GSK Investigational Site
Colorado Springs, Colorado, United States, 80907
GSK Investigational Site
Littleton, Colorado, United States, 80120
United States, Connecticut
GSK Investigational Site
Bridgeport, Connecticut, United States, 06606
GSK Investigational Site
Farmington, Connecticut, United States, 06030
GSK Investigational Site
Guilford, Connecticut, United States, 06437
United States, District of Columbia
GSK Investigational Site
Washington, District of Columbia, United States, 20010
GSK Investigational Site
Washington, District of Columbia, United States, 20017
United States, Florida
GSK Investigational Site
Aventura, Florida, United States, 33180
GSK Investigational Site
Bay Pines, Florida, United States, 33744
GSK Investigational Site
Daytona Beach, Florida, United States, 32114
GSK Investigational Site
Delray Beach, Florida, United States, 33484
GSK Investigational Site
Fort Meyers, Florida, United States, 33919
GSK Investigational Site
Gainesville, Florida, United States, 32605
GSK Investigational Site
Hudson, Florida, United States, 34667
GSK Investigational Site
Jacksonville, Florida, United States, 32207
GSK Investigational Site
Jacksonville, Florida, United States, 32216
GSK Investigational Site
Jupiter, Florida, United States, 33458
GSK Investigational Site
Kissimmee, Florida, United States, 34741
GSK Investigational Site
Largo, Florida, United States, 33773
GSK Investigational Site
Melbourne, Florida, United States, 32901
GSK Investigational Site
Miami, Florida, United States, 33136
GSK Investigational Site
Miami, Florida, United States, 33137
GSK Investigational Site
Miami, Florida, United States, 33176
GSK Investigational Site
Ocala, Florida, United States, 34471
GSK Investigational Site
Orlando, Florida, United States, 32803
GSK Investigational Site
Ormond Beach, Florida, United States, 32174
GSK Investigational Site
Pensacola, Florida, United States, 32514
GSK Investigational Site
Pinellas Park, Florida, United States, 33781
GSK Investigational Site
Tampa, Florida, United States, 33607
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30342
GSK Investigational Site
Atlanta, Georgia, United States, 30328
GSK Investigational Site
Atlanta, Georgia, United States, 30322
GSK Investigational Site
Decatur, Georgia, United States, 30030
GSK Investigational Site
Tucker, Georgia, United States, 30084
United States, Illinois
GSK Investigational Site
Bannockburn, Illinois, United States, 60015
GSK Investigational Site
Gurnee, Illinois, United States, 60031
GSK Investigational Site
Normal, Illinois, United States, 61761
GSK Investigational Site
Peoria, Illinois, United States, 61603
United States, Indiana
GSK Investigational Site
Elkhart, Indiana, United States, 46514
GSK Investigational Site
Indianapolis, Indiana, United States, 46260
GSK Investigational Site
La Porte, Indiana, United States, 46350
GSK Investigational Site
South Bend, Indiana, United States, 46601
United States, Kansas
GSK Investigational Site
Kansas City, Kansas, United States, 66102
United States, Kentucky
GSK Investigational Site
Louisville, Kentucky, United States, 40205
GSK Investigational Site
Mount Sterling, Kentucky, United States, 40353
United States, Louisiana
GSK Investigational Site
Covington, Louisiana, United States, 70433
GSK Investigational Site
Lacombe, Louisiana, United States, 70445
United States, Maine
GSK Investigational Site
Auburn, Maine, United States, 04210
GSK Investigational Site
Biddeford, Maine, United States, 04005
GSK Investigational Site
Portland, Maine, United States, 04106
GSK Investigational Site
Scarborough, Maine, United States, 04074
United States, Maryland
GSK Investigational Site
Annapolis, Maryland, United States, 20401
United States, Massachusetts
GSK Investigational Site
Ayer, Massachusetts, United States, 01432
GSK Investigational Site
Brookline, Massachusetts, United States, 02446
GSK Investigational Site
Worcester, Massachusetts, United States, 01655
United States, Michigan
GSK Investigational Site
Alpena, Michigan, United States, 49707
GSK Investigational Site
Cadillac, Michigan, United States, 49601
GSK Investigational Site
Detroit, Michigan, United States, 48201
GSK Investigational Site
Kalamazoo, Michigan, United States, 49048
GSK Investigational Site
Lansing, Michigan, United States, 48910
United States, Minnesota
GSK Investigational Site
Mineappolis, Minnesota, United States, 55417
GSK Investigational Site
Rochester Hills, Minnesota, United States, 48307
GSK Investigational Site
St Paul, Minnesota, United States, 55102
United States, Mississippi
GSK Investigational Site
Gulfport, Mississippi, United States, 39503
United States, Montana
GSK Investigational Site
Billings, Montana, United States, 59101
GSK Investigational Site
Kalispell, Montana, United States, 59901
GSK Investigational Site
Missoula, Montana, United States, 59802
United States, New Jersey
GSK Investigational Site
Morristown, New Jersey, United States, 07962
GSK Investigational Site
Summit, New Jersey, United States, 07901
GSK Investigational Site
Wayne, New Jersey, United States, 07470
United States, New York
GSK Investigational Site
Babylon, New York, United States, 11702
GSK Investigational Site
Buffalo, New York, United States, 14215
GSK Investigational Site
Buffalo, New York, United States, 14209
GSK Investigational Site
Mineola, New York, United States, 11501
GSK Investigational Site
New York, New York, United States, 10025
GSK Investigational Site
New York, New York, United States, 10029
GSK Investigational Site
New York, New York, United States, 10032
GSK Investigational Site
New York, New York, United States, 10021
GSK Investigational Site
Troy, New York, United States, 12180
GSK Investigational Site
West Islip, New York, United States, 11794
United States, North Carolina
GSK Investigational Site
Charlotte, North Carolina, United States, 28203
GSK Investigational Site
Charlotte, North Carolina, United States, 28080
GSK Investigational Site
Hickory, North Carolina, United States, 28601
GSK Investigational Site
Statesville, North Carolina, United States, 28625
United States, North Dakota
GSK Investigational Site
Grand Forks, North Dakota, United States, 58201
United States, Ohio
GSK Investigational Site
Akron, Ohio, United States, 44304
GSK Investigational Site
Bryan, Ohio, United States, 43506
GSK Investigational Site
Cincinnati, Ohio, United States, 45219
GSK Investigational Site
Cleveland, Ohio, United States, 44106
GSK Investigational Site
Fairview Park, Ohio, United States, 44126
United States, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73103
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73109
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
GSK Investigational Site
Corvalis, Oregon, United States, 97330
GSK Investigational Site
Hillsboro, Oregon, United States, 97123-4117
GSK Investigational Site
Portland, Oregon, United States, 97220
GSK Investigational Site
Portland, Oregon, United States, 97223
United States, Pennsylvania
GSK Investigational Site
Beaver, Pennsylvania, United States, 15009
GSK Investigational Site
Greensburg, Pennsylvania, United States, 15601
GSK Investigational Site
Hershey, Pennsylvania, United States, 17033
GSK Investigational Site
Langhorne, Pennsylvania, United States, 19047
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19102
GSK Investigational Site
Ridley Park, Pennsylvania, United States, 19078
GSK Investigational Site
West Chester, Pennsylvania, United States, 19380
GSK Investigational Site
Wynnewood, Pennsylvania, United States, 19096
GSK Investigational Site
Wyomissing, Pennsylvania, United States, 19610
United States, Rhode Island
GSK Investigational Site
Cranston, Rhode Island, United States, 02920
GSK Investigational Site
Pawtucket, Rhode Island, United States, 02860
GSK Investigational Site
Westerly, Rhode Island, United States, 02891
United States, South Carolina
GSK Investigational Site
Greer, South Carolina, United States, 29651
GSK Investigational Site
Spartanburg, South Carolina, United States, 29302
United States, South Dakota
GSK Investigational Site
Sioux Falls, South Dakota, United States, 57105
United States, Tennessee
GSK Investigational Site
Jackson, Tennessee, United States, 38301
GSK Investigational Site
Memphis, Tennessee, United States, 38120
United States, Texas
GSK Investigational Site
Austin, Texas, United States, 78705
GSK Investigational Site
Beaumont, Texas, United States, 77702
GSK Investigational Site
Corpus Christi, Texas, United States, 78404
GSK Investigational Site
Dallas, Texas, United States, 75231
GSK Investigational Site
Dallas, Texas, United States, 75230
GSK Investigational Site
Houston, Texas, United States, 77090
GSK Investigational Site
Houston, Texas, United States, 77074
GSK Investigational Site
Humble, Texas, United States, 77338
GSK Investigational Site
Lubbock, Texas, United States, 79410
GSK Investigational Site
McKinney, Texas, United States, 75069
GSK Investigational Site
Odessa, Texas, United States, 79761
GSK Investigational Site
Odessa, Texas, United States, 79764
GSK Investigational Site
Orange, Texas, United States, 77630
GSK Investigational Site
Tyler, Texas, United States, 75701
GSK Investigational Site
Waco, Texas, United States, 76712
United States, Utah
GSK Investigational Site
Salt Lake City, Utah, United States, 84124
United States, Virginia
GSK Investigational Site
Arlington, Virginia, United States, 22204
GSK Investigational Site
Chesapeake, Virginia, United States, 23510
GSK Investigational Site
Galax, Virginia, United States, 24333
GSK Investigational Site
Richlands, Virginia, United States, 24641
GSK Investigational Site
Richmond, Virginia, United States, 23294
GSK Investigational Site
Richmond, Virginia, United States, 23249
GSK Investigational Site
Springfield, Virginia, United States, 22151
United States, Washington
GSK Investigational Site
Burien, Washington, United States, 98166
United States, West Virginia
GSK Investigational Site
Huntington, West Virginia, United States, 25701
United States, Wisconsin
GSK Investigational Site
Beloit, Wisconsin, United States, 53511
GSK Investigational Site
Madison, Wisconsin, United States, 53792
GSK Investigational Site
Marshfield, Wisconsin, United States, 54449
GSK Investigational Site
Milwaukee, Wisconsin, United States, 53215
GSK Investigational Site
Wausau, Wisconsin, United States, 54401
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00402363     History of Changes
Other Study ID Numbers: OM8 Afib
Study First Received: November 20, 2006
Results First Received: September 23, 2010
Last Updated: February 7, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Lovaza
Omega-3 fatty acids
Omacor
Paroxysmal atrial fibrillation

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 18, 2014